Dr. Sagar A. Patel, MD
Claim this profileEmory Saint Joseph's Hospital
Studies Prostate Cancer
Studies Skin Cancer
5 reported clinical trials
16 drugs studied
Area of expertise
1Prostate Cancer
Stage I
Stage II
2Skin Cancer
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Sagar A. Patel, MD is currently running
Relugolix + Abiraterone Acetate vs Leuprolide + Abiraterone Acetate
for Prostate Cancer
This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy. Leuprolide is in a class of medications called gonadotropin-releasing hormone agonists (GNRHa). It prevents the body from making luteinizing hormone-releasing hormone (LHRH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone (a male hormone) in men and may stop the growth of prostate tumor cells that need testosterone to grow. Abiraterone acetate, an androgen biosynthesis inhibitor, works by decreasing the amount of certain hormones in the body. Relugolix, a GNRH antagonist, works by decreasing the amount of testosterone produced by the body. This may slow or stop the spread of prostate tumor cells that need testosterone to grow. The use of hormone therapy with radiation therapy has been shown to improve survival, however, studies have suggested that the addition of hormone therapy may worsen heart (cardiac) disease and high blood pressure. In fact, studies have shown that the most common cause of death in prostate cancer patients is due to heart disease or heart attacks. Computed tomography (CT) scans create a series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine. In this study, sophisticated cardiac CT images are used to take pictures of patients' heart and coronary arteries to help assess damage to the heart. Using cardiac CT and blood tests, this trial may help doctors determine which patients are at risk of cardiac disease when treated with combination hormone therapy, as well as the differential risk of leuprolide versus relugolix in combination with abiraterone acetate.
Recruiting2 awards Phase 35 criteria
Pegylated Interferon Alfa-2a
for Myelofibrosis
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.
Recruiting1 award Phase 1
More about Sagar A. Patel, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sagar A. Patel, MD has experience with
- Leuprolide
- Relugolix
- Abiraterone Acetate
- Radiation Therapy
- Pegylated Interferon Alfa-2a
- Photon
Breakdown of trials Sagar A. Patel, MD has run
Prostate Cancer
Skin Cancer
Acute Myeloid Leukemia
Myelofibrosis
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sagar A. Patel, MD specialize in?
Sagar A. Patel, MD focuses on Prostate Cancer and Skin Cancer. In particular, much of their work with Prostate Cancer has involved Stage I patients, or patients who are Stage II.
Is Sagar A. Patel, MD currently recruiting for clinical trials?
Yes, Sagar A. Patel, MD is currently recruiting for 3 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Sagar A. Patel, MD has studied deeply?
Yes, Sagar A. Patel, MD has studied treatments such as Leuprolide, Relugolix, Abiraterone Acetate.
What is the best way to schedule an appointment with Sagar A. Patel, MD?
Apply for one of the trials that Sagar A. Patel, MD is conducting.
What is the office address of Sagar A. Patel, MD?
The office of Sagar A. Patel, MD is located at: Emory Saint Joseph's Hospital, Atlanta, Georgia 30342 United States. This is the address for their practice at the Emory Saint Joseph's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.